Natco Pharma (NATCOPHARM)

FairStock Score: 66/100 — STEADY

Score breakdown: P/E: 3/3 · ROCE: 2/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

Strengths

• High ROE of 20.47% and ROCE of 32.78% suggest strong capital efficiency and a competitive position.
• Near-zero debt/equity of 0.03 gives enormous financial flexibility in a capital-intensive industry.
• Positive free cash flow of ₹261 Cr and a Piotroski F-score of 8/9 indicate solid earnings quality and balance sheet health.
• Promoter holding of 49.48% aligns management interests with minority shareholders.
• Five-year revenue CAGR of 16.64% demonstrates a historical track record of growth despite a slower recent year.

Concerns

• Profit growth fell 16.51%, and latest sales growth is only 6.63%, showing near-term earnings momentum has stalled.
• Price of ₹1,071.45 is 18% above Graham Number of ₹906.59, leaving no margin of safety under conservative valuation.
• DCF intrinsic value of ₹356.65 is far below market price, implying the market has priced in aggressive future growth.
• Dividend yield of 0.61% offers negligible income; returns depend almost entirely on capital gains.

AI Analysis

Let me think about this like a business owner, not a trader. Natco Pharma earns an ROE of 20.47% and an ROCE of 32.78%; those returns tell me the business has a genuine advantage in deploying capital. With debt-to-equity of only 0.03, I am not losing sleep over the balance sheet. Free cash flow of ₹261 Cr and a Piotroski F-score of 8/9 confirm that accounting earnings are translating into real cash and the business is financially healthy. Promoter holding of 49.48% also tells me the people running Natco are eating their own cooking. Still, a good business is not automatically a good investment. Sales growth is just 6.63% and profit growth has fallen 16.51%, so the recent quarter is not inspiring. The five-year revenue CAGR of 16.64% shows what this company can do, but I need evidence that the growth engine is running again. Latest quarter sales of ₹647 Cr and net profit of ₹151 Cr are respectable, but the trend matters more. On valuation, I have to be demanding. At ₹1,071.45, the P/E is 11.37, which seems reasonable at first glance. Yet Graham's number is ₹906.59, so the price is about 18% beyond that conservative ceiling. My DCF value of ₹356.65 is far lower, and that tells me the market is assuming a great deal of future optimism. With a margin of safety of -9.03%, I cannot honestly call this a bargain. The Altman Z-score of 3.33 and the 80/100 screen score make me look twice, but they do not replace the price I pay. I will put Natco on my watchlist. The operating quality is there; the margin of safety is not. I wait for a better price or for earnings to reaccelerate. In investing, patience and price are everything.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer